Müller Hermann L
Department of Pediatrics and Pediatric Hematology/Oncology, University Children's Hospital, Carl von Ossietzky Universität Oldenburg, Klinikum Oldenburg AöR, Rahel-Straus-Strasse 10, 26133, Oldenburg, Germany.
J Neurooncol. 2025 Jun;173(2):233-244. doi: 10.1007/s11060-025-04987-1. Epub 2025 Mar 17.
After diagnosis and management of childhood-onset craniopharyngioma, patients frequently develop a rapid weight gain starting in the first 6-12 months after diagnosis and leading to morbid hypothalamic obesity due to disease- and/or treatment-associated hypothalamic lesions.
A scoping review was performed after search of the MEDLINE/PubMed, Embase, and Web of Science databases for initial identification of articles. The search terms craniopharyngioma, hypothalamic obesity, and quality of life were used.
Hypothalamic obesity should be diagnosed and treated in the context of hypothalamic syndrome. Hypothalamic nuclei are the key-regulators of our body homeostasis. Hypothalamic syndrome includes endocrine deficiencies of hypothalamic-pituitary axes, disruption of circadian rhythm, disturbed hunger-satiety and thirst feelings, temperature dysregulation, and neurocognitive, sleep and psychosocial behavioral problems. Consequently, patients with hypothalamic syndrome develop hypothalamic obesity, chronic fatigue, increased daytime sleepiness and mood disorders resulting in isolation, school drop-out and inability to participate in daily life. Long-term follow-up is frequently impaired by increased risk for metabolic syndrome, cardiovascular health problems, severe impairments of health-related quality of life, and premature mortality. Treatment of hypothalamic syndrome is challenging. Hypothalamic syndrome is not a ,one-size-fits-all- disease, which may not require a ,one-size-fits-all- management. Recently, an algorithm for personalized, risk-specific treatment of hypothalamic syndrome after CP has been published. Dextro-amphetamines and other central stimulating agents (modafinil, methylphenidate) may cause weight loss, especially in children with hyperphagia or decreased resting-energy expenditure. Reports on the use of glucagon-like peptide-1 receptor (GLP-1R) agonists for acquired hypothalamic obesity have been contradictory, with successful reports but also series with limited results. Bariatric surgery is effective. However, non-reversible procedures are controversial due to ethical and legal considerations in minors.
Hypothalamus-sparing treatment strategies and further research on novel therapeutic agents for hypothalamic syndrome are warranted.
儿童期颅咽管瘤经诊断和治疗后,患者常在诊断后的最初6至12个月开始体重迅速增加,并由于疾病和/或治疗相关的下丘脑病变导致病态下丘脑肥胖。
在检索MEDLINE/PubMed、Embase和Web of Science数据库以初步识别文章后进行了一项范围综述。使用了“颅咽管瘤”“下丘脑肥胖”和“生活质量”等检索词。
下丘脑肥胖应在下丘脑综合征的背景下进行诊断和治疗。下丘脑核是我们身体内环境稳态的关键调节者。下丘脑综合征包括下丘脑 - 垂体轴的内分泌缺陷、昼夜节律紊乱、饥饿 - 饱腹感和口渴感紊乱、体温调节失调以及神经认知、睡眠和社会心理行为问题。因此,下丘脑综合征患者会出现下丘脑肥胖、慢性疲劳、白天嗜睡增加和情绪障碍,导致社交隔离、辍学以及无法参与日常生活。长期随访常因代谢综合征风险增加、心血管健康问题、健康相关生活质量严重受损和过早死亡而受到影响。下丘脑综合征的治疗具有挑战性。下丘脑综合征不是一种“一刀切”的疾病,可能不需要“一刀切”的管理方法。最近,已发表了一种针对颅咽管瘤后下丘脑综合征的个性化、风险特异性治疗算法。右旋苯丙胺和其他中枢兴奋剂(莫达非尼、哌甲酯)可能导致体重减轻,尤其是在食欲亢进或静息能量消耗降低的儿童中。关于使用胰高血糖素样肽 -1受体(GLP-1R)激动剂治疗获得性下丘脑肥胖的报道相互矛盾,有成功的报道,但也有效果有限的系列报道。减肥手术是有效的。然而,由于未成年人的伦理和法律考虑,不可逆手术存在争议。
有必要采取保留下丘脑的治疗策略,并进一步研究针对下丘脑综合征的新型治疗药物。